VeraDermics
WEST HARTFORD, Connecticut, United States · Healthcare, Health Care
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on turning everyday dermatology and aesthetics problems into clear, proven care. We are on a mission to make long-ignored dermatology and aesthetics conditions simple, replacing false hope, confusion, and questionable results with solutions that people and providers can trust. Our lead investig
Key facts
- Headquarters
- WEST HARTFORD, Connecticut, United States
- Employees
- Unknown
- Industries
- Healthcare, Health Care
- Status
- Public (MANE)
- Website
- www.veradermics.com
- Company page
Recent activity at VeraDermics
- : SEC 8-K (8.01): On October 19, 2026, the Company announced positive topline data from its Phase 3 clinical trial (Study ‘304’) evaluating VDPHL01 for treating mild-to-moderate pattern hair loss in males. The study involved 536 patients and met all primary and secondary endpoints with statistically significant results, showing substantial increases in hair count and favorable tolerability. Specifically, the QD and BID treatment arms saw average increases of 28.6 and 36.4 hairs/cm², respectively, versus a 6.6 hairs/cm² increase in the placebo group. The results indicate a promising clinical profile for VDPHL01, which may lead to effective treatment options for hair loss, supported by the safety findings consistent with previous studies and no serious adverse events reported.
- : SEC 8-K (8.01): On July 15, 2026, the Company announced positive topline results from Study '207' evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation for females with mild-to-moderate pattern hair loss. The Phase 2 trial included 21 male and 28 female participants, testing VDPHL01 at various dosages over 6 months. Results demonstrated significant hair growth in participants, with substantial improvements in hair count as well as high tolerance to the treatment. Key findings included an average increase of 22.7 hairs/cm² and 90% of participants reporting substantial improvement in hair coverage. The study's implications suggest VDPHL01 may offer a new effective treatment option for pattern hair loss, supported by positive safety profiles and minimal adverse effects.
- : VeraDermics
- : SEC 8-K (1.01): On May 1, 2026, Veradermics, Incorporated closed its underwritten public offering of 3,843,790 shares of common stock at a public offering price of $100.00 per share, raising substantial funds. Concurrently, they closed a private placement with certain investors affiliated with Suvretta Capital, selling pre-funded warrants to purchase 300,000 shares at an offering price of $99.99999 per warrant, yielding gross proceeds of approximately $30.0 million. The exercise price of the warrants is $0.00001 per underlying share and is subject to adjustments for stock changes. The purchase agreement contains various customary terms including representations and warranties, along with a restriction period on issuing new shares for 90 days following the agreement date of April 29, 2026.
- : SEC 8-K (7.01): On April 27, 2026, Veradermics, Incorporated announced positive topline data from their Phase 2/3 clinical trial, Study '302', which is evaluating VDPHL01 for males experiencing mild-to-moderate pattern hair loss. This announcement was made through a press release and was accompanied by a presentation during a conference call and webcast. The press release and presentation are included as Exhibits 99.1 and 99.2 within the filing. The positive results may have significant strategic implications for the company's product development and market positioning in the hair loss treatment sector.
- : SEC 8-K (8.01): On April 27, 2026, the Company announced positive topline data from the Phase 2/3 clinical trial, Study ‘302’, evaluating VDPHL01 in males with mild-to-moderate pattern hair loss. The study involved 519 patients and reported significant improvements in hair count and patient satisfaction compared to placebo, demonstrating a strong clinical efficacy with a notable safety profile. The study met all primary and key secondary endpoints, highlighting that 79.3% of patients in the QD arm and 86.0% in the BID arm reported improvement on the AAIRS at Month 6, with rapid onset of hair growth observed as early as Month 2. The findings suggest a robust therapeutic potential for VDPHL01 in treating hair loss, with statistical significance (p<0.0001) at various endpoints and no serious adverse events reported, which may impact the company's market position and future product development.
- : Veradermics has completed an oversubscribed $150 million Series C financing led by SR One to advance its lead product VDPHL01 through Phase 3 trials for hair regrowth.
- : Veradermics Names Reid Waldman as Chief Executive Officer
- : VeraDermics
- : VeraDermics
VeraDermics funding history
| Date | Round | Amount |
|---|---|---|
| May 2026 | Venture | $30.0M |
| Oct 2025 | Series C | $150.0M |
| Dec 2024 | Venture | $66.6M |
| May 2023 | Venture | $15.0M |
| Oct 2021 | Venture | $22.2M |
Leadership
- Timothy Durso, Executive Officer, Director
- Reid Waldman, Executive Officer, Director
- Dominic Carrano, Chief Financial Officer
Verified email and direct lines for VeraDermics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
VeraDermics in the news
- Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study - Reuters (Oct 19, 2026)
- Veradermics builds $820m war chest for oral hair loss pill - Longevity.Technology (Sep 03, 2026)
- Veradermics’ hair loss drug succeeds in late-stage trial - STAT (Apr 27, 2026)
- Phase 2/3 Trial of Extended-Release Oral Minoxidil Shows Robust Hair Growth Outcomes in Male Pattern Hair Loss - Dermatology Times (Apr 27, 2026)
- Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Business Wire (Aug 11, 2026)
- Veradermics Advances VDPHL01 in Phase 2/3 Clinical Trial for Female Pattern Hair Loss, Marking a Milestone in the Development of the Potential First-Ever Oral Prescription Treatment for Women - BioSpace (Nov 19, 2025)
- Veradermics' hot streak continues with another phase 3 win in hair loss - Fierce Pharma (Oct 20, 2026)
- Veradermics’ stock up on male hair loss trial success - Clinical Trials Arena (Oct 19, 2026)
Companies similar to VeraDermics
- eHealth · Healthcare, Health Care
- iSpecimen · Healthcare, Health Care
- Olema Pharmaceuticals, Inc. · Healthcare, Health Care
- Ceribell · Healthcare, Health Care
- Oruka Therapeutics · Healthcare, Health Care
About VeraDermics: questions and answers
What does VeraDermics do?
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on turning everyday dermatology and aesthetics problems into clear, proven care. We are on a mission to make long-ignored dermatology and aesthetics conditions simple, replacing false hope, confusion, and questionable results with solutions that people and providers can trust. Our lead investig
Where is VeraDermics headquartered?
VeraDermics is headquartered in WEST HARTFORD, Connecticut, United States.
Has VeraDermics raised funding?
Yes. Fundz has recorded 5 funding events for VeraDermics. The most recent, $30.0M, was in May 2026.
What is the latest news on VeraDermics?
On Oct 19, 2026, SEC 8-K (8.01): On October 19, 2026, the Company announced positive topline data from its Phase 3 clinical trial (Study ‘304’) evaluating VDPHL01 for treating mild-to-moderate pattern hair loss in males. The study involved 536 patients and met all primary and secondary endpoints with statistically s
Is VeraDermics a public company?
Yes. VeraDermics is publicly traded under the ticker MANE.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy